Prostate cancer is the most common non-­skin cancer in men and the second leading cause of cancer death in the Western world, including the UK. At present, prostate cancer is most often diagnosed at a clinically localised disease stage following blood testing for prostate­-specific antigen (PSA). However, approximately a quarter of men treated with surgery or radiotherapy for clinically localised prostate cancer will experience return of the disease. If the disease progresses to metastatic prostate cancer the treatment options at that stage are limited and mainly palliative.

The objective of the IMPROVE consortium is to develop an effective vaccine against prostate cancer to the point of Phase II testing in the UK.